Moscow city is to become center for production of essential drugs in Russia

The Russian capital Moscow is expected to be one of the centers for the production of new vital and essential drugs in the country already in the short term as its pharmaceutical output is steadily growing, according to recent statements by the Moscow city senior state officials and local media, reports The Pharma Letter’s local correspondent.

As part of this a new large-scale production of essential drugs will be launched by the Moscow-based Amedart company. The range of the drugs that will be produced on the basis of the new plant will exceed 20 units. These will be drugs for the treatment of cancer, HIV, diabetes, blood clots, tuberculosis and other serious diseases.

The majority of funds for the project will be allocated from the company’s own resources, while the remaining will be provided by the Industrial Development Fund – a public fund in Russia, which funds various investment projects in the field of pharmaceutics. It is planned, the new production will allow to partially replace some original foreign drugs in the Russian market.